Semaglutide GLP-1 effectiveness in inducing weight loss has been observed, making it a popular choice for many of our patients
However, patients with established cardiovascular disease, particularly those with heart failure or arrhythmias, may benefit from more structured monitoring
For semaglutide, Beggs test showed no evidence of bias (Kendalls tau b = 0.03571, p = 0.90154), and Eggers test also indicated no small-study effects (intercept = -0.18380, p = 0.58764)
Be sure to tell them if any of the following factors apply to you: previous allergic reaction to Ozempic or other GLP-1 receptor agonists (the group of drugs Ozempic belongs to) diabetic retinopathy use of insulin or other diabetes drugs planned surgery conditions that cause severely slow digestion dehydration resulting from nausea, vomiting, or diarrhea pregnancy breastfeeding alcohol consumption Medical Perspective Can switching GLP-1 medications help with negative side effects
Hazard ratios (HRs), 95% confidence intervals (CIs) and p values for stroke were calculated using a Cox proportional hazards model, with DPP4i as the reference group
I typically reassess patients one month after initiation and then every three months once a stable dose is achieved, Dr
